A review proposes CB2 cannabinoid receptors as therapeutic targets for HIV-associated neurocognitive disorder, noting that HIV patients using medical marijuana have lower levels of inflammatory monocytes.
HIV/AIDS researchers, neuroimmunologists, and pharmacologists developing CB2-selective drugs.
50% of HIV patients develop brain inflammation; cannabis users showed fewer inflammatory monocytes
What the researchers found
HIV patients using medical marijuana had lower levels of circulating CD16+ (activated) monocytes compared to non-cannabis users. CD16+ monocytes carry HIV across the blood-brain barrier and drive neuroinflammation in HAND. CB2 receptor activation suppresses monocyte activation, chemotaxis, and inflammatory mediator release. The review proposes CB2 as a therapeutic target because it mediates anti-inflammatory effects without the psychotropic properties associated with CB1.
Why it matters
About 50% of HIV patients develop neurocognitive dysfunction despite antiretroviral therapy. Current treatments do not adequately address the neuroinflammation driving HAND. CB2-targeted therapy could reduce brain inflammation without psychotropic effects.
The numbers in context
~38 million people living with HIV; ~50% develop HAND; HIV patients on medical marijuana showed lower CD16+ monocyte levels than non-users.
How the study worked
Narrative review synthesizing evidence on HAND pathophysiology, endocannabinoid immunology, and clinical observations in HIV patients using medical cannabis, proposing CB2 as a therapeutic target.
What this study cannot tell us
Review based on observational clinical data and preclinical mechanistic studies; no RCTs of CB2 agonists for HAND; lower CD16+ monocytes in cannabis users could reflect confounding; CB2-selective drugs are not yet clinically available.
How to read the evidence
Moderate: well-reasoned mechanistic review with clinical observations, but no direct CB2-targeted clinical trials.
When this study was published
Published 2020.
The bigger picture
If CB2 agonists can reduce the activated monocytes that carry HIV into the brain, this approach could complement antiretroviral therapy by addressing the inflammatory component that current drugs miss.
Questions still open
- Would a CB2-selective agonist reduce HAND progression in a clinical trial? Does whole cannabis use improve neurocognitive outcomes in HIV patients?
Common questions
Can cannabis help with HIV-related brain problems?
What is HAND?
Read the original research
Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 15(4), 780-793
Citation
Rizzo, Michael D; Henriquez, Joseph E; Blevins, Lance K; Bach, Anthony; Crawford, Robert B; Kaminski, Norbert E. (2020). Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 15(4), 780-793. https://doi.org/10.1007/s11481-020-09918-7
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk